Atopic dermatitis (AD), also known as atopic eczema, is a chronic, pruritic, relapsing inflammatory dermatological condition. Early disease management includes moisturizers, avoiding the factors that trigger AD, and patient education. Treatment mainly aims at reducing itch and inflammation, eliminating flare-ups, and reducing side effects.



Topical agents are considered as a primary treatment for mild to moderate AD and include topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), and phosphodiesterase 4 (PDE4) inhibitor. More recently, the first topical selective Janus kinase (JAK)1/JAK2 inhibitor has been approved for use in patients with mild to moderate disease.

• How will the availability of a topical selective JAK impact your use of TCS, TCI, or PDE4 in mild to moderate AD patients?


• In which types of patients do you foresee the greatest utility of a topical selective JAK in the treatment of mild to moderate AD patients?

Atopic dermatitis (AD), also known as atopic eczema, is a chronic, pruritic, relapsing inflammatory dermatological condition. Early disease management includes moisturizers, avoiding the factors that trigger AD, and patient education. Treatment mainly aims at reducing itch and inflammation, eliminating flare-ups, and reducing side effects.



Topical agents are considered as a primary treatment for mild to moderate AD and include topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), and phosphodiesterase 4 (PDE4) inhibitor. More recently, the first topical selective Janus kinase (JAK)1/JAK2 inhibitor has been approved for use in patients with mild to moderate disease.

• How will the availability of a topical selective JAK impact your use of TCS, TCI, or PDE4 in mild to moderate AD patients?


• In which types of patients do you foresee the greatest utility of a topical selective JAK in the treatment of mild to moderate AD patients?

Atopic dermatitis (AD), also known as atopic eczema, is a chronic, pruritic, relapsing inflammatory dermatological condition. Early disease management includes moisturizers, avoiding the factors that trigger AD, and patient education. Treatment mainly aims at reducing itch and inflammation, eliminating flare-ups, and reducing side effects.



Topical agents are considered as a primary treatment for mild to moderate AD and include topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), and phosphodiesterase 4 (PDE4) inhibitor. More recently, the first topical selective Janus kinase (JAK)1/JAK2 inhibitor has been approved for use in patients with mild to moderate disease.

• How will the availability of a topical selective JAK impact your use of TCS, TCI, or PDE4 in mild to moderate AD patients?


• In which types of patients do you foresee the greatest utility of a topical selective JAK in the treatment of mild to moderate AD patients?

Atopic dermatitis (AD), also known as atopic eczema, is a chronic, pruritic, relapsing inflammatory dermatological condition. Early disease management includes moisturizers, avoiding the factors that trigger AD, and patient education. Treatment mainly aims at reducing itch and inflammation, eliminating flare-ups, and reducing side effects.



Topical agents are considered as a primary treatment for mild to moderate AD and include topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), and phosphodiesterase 4 (PDE4) inhibitor. More recently, the first topical selective Janus kinase (JAK)1/JAK2 inhibitor has been approved for use in patients with mild to moderate disease.

• How will the availability of a topical selective JAK impact your use of TCS, TCI, or PDE4 in mild to moderate AD patients?


• In which types of patients do you foresee the greatest utility of a topical selective JAK in the treatment of mild to moderate AD patients?